X

Drug Profile

Baclofen/samidorphan

Alternative Names: ALKS-29; ALKS-33/baclofen; Baclofen/ALKS-33

Latest Information Update: 26 Sep 2011

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alkermes
Class Aminobutyric acids; Drug withdrawal therapies; Small molecules
Mechanism of Action GABA B receptor agonists; Opioid mu receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Alcoholism

Most Recent Events

05 Dec 2008 Alkermes initiates a Phase-I trial for Alcoholism in the USA
31 Jul 2008 Phase I/II development is ongoing in the US
06 Jul 2007 Results from a phaseI/II clinical trial in patients with alcoholism added to the adverse events and Drug Withdrawal therapeutic trials sections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com